Advocating for Impact: Empowering Pharmacists to Treat Opioid Use Disorder

Prior to 2023, the “X-waiver” requirement prohibited pharmacists from prescribing buprenorphine as treatment for opioid use disorder (OUD). Now that the X-waiver has been eliminated, pharmacists now have more flexibility to engage in team-based OUD treatment via collaborative practice. This podcast will explore potential practice models relating to pharmacist-provided OUD treatment, review current laws and limitations on pharmacists engaging in controlled substance prescribing, and discuss advocacy initiatives to enhance pharmacists’ role as treatment providers.  The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.